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Objectives: The present study aimed at investigating the impact of mandatory 
clinical clerkship courses on fifth year pharmacy students’ attitudes and perceived 
barriers toward providing pharmaceutical care (PC). MethOds: A cross-sectional 
survey was conducted among 5th year pharmacy students undertaking manda-
tory clinical clerkship in the University of Gondar, Ethiopia. A pharmaceutical care 
attitudes survey (PCAS) questionnaire was used to assess the attitude (14 items), 
commonly identified drug-related problem/s (1 item) during clerkships, and per-
ceived barriers (12 items) toward the provision of PC. Statistical analysis was con-
ducted on the retrieved data. Results: Among the total of 69 clerkship students, 
65 participated and completed the survey (94.2% response rate). Overall, 74.45% 
of participants had positive attitude toward PC provision. Almost all respondents 
agreed that the primary responsibility of pharmacists in the healthcare setting was 
to prevent and solve medication-related problems (98.5%), practice of PC was valu-
able (89.3%), and the PC movement will improve patient health (95.4%), respectively. 
Unnecessary drug therapy (43%), drug-drug interactions (33%), and non-adherence 
to medications (33%) were the most common drug-related problems identified in 
wards. Highly perceived barriers for PC provision included lack of a workplace for 
counseling in the pharmacy (75.4%), a poor image of pharmacist’s role in wards 
(67.7%), and inadequate technology in the pharmacy (64.6%). Lack of access to a 
patient’s medical record in the pharmacy had significant association (P< 0.05) with 
PC practice, performance of PC during clerkship and provision of PC as clinical 
pharmacists cOnclusiOns: Students attending the new clinical pharmacy pro-
gram in Ethiopia have a good attitude toward pharmaceutical care. However, the 
barriers to pharmaceutical care need to be addressed by integrating PC provision 
with pharmacy practice.
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Objectives: Aim of this research was to investigate ideal attribution with revealing 
the relevance between pharmacy attribution and patients’ outcomes. MethOds: A 
self-completion questionnaire from composed of two forms of “Pharmacy attribute” 
and “Patients attribute” was delivered to 3321 pharmacies across Japan which agreed 
to join in January 2013. Pharmacy attribute: a number of pharmacist, prescription/
day, home-visiting patients/ month, cooperated medical facilities. Patients attribute: 
adverse drug event, change in prescription, change in adherence, finding of unused 
drugs, and change in the amount of unused drugs. We grouped by 2 indexes (a num-
ber of prescription/day/pharmacist as ‘work load’ and cooperated medical facilities 
as ‘positivity to cooperate’) to 4 groups. (Used SPSS ver.21) Results: Among 1,890 
community pharmacies data (collecting rate: 56.9%), we extracted answers to all 
the question items about community pharmacy attribute necessary for grouping. 
The 1,327 community pharmacies data was collected as the target (the number of 
patient data: for 4,947) for the analysis. The data of 1327 pharmacies showed the 
middle of attribution showed 20 prescriptions filled /day/pharmacist (work load) 
and 1 medical facility cooperated. The group of ‘Prescriptions≦20 and Cooperated 
facility> 1’ and the groups of ‘Prescriptions> 20 and Cooperated facility> 1’ 
changed in prescription(p< 0.003), changed in adherence(p< 0.001), find of unused 
drugs(p< 0.001), and decreased the amount of unused drugs (p< 0.001) more than 
others. There is no significant differences in adverse drug event. cOnclusiOns: 
It was suggested that there was relationship between pharmacy attribution (work 
load/ positivity to cooperate) and patient’s outcomes on healthcare service of home-
visiting.
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Objectives: This study was conducted to assess the knowledge, attitude and 
practice of community pharmacists (CPs) towards ADR reporting and monitor-
ing. MethOds: A prospective cross sectional study was conducted at selected 
community pharmacies. Pharmacists at selected pharmacies were administered 
a questionnaire by research pharmacist and two weeks’ time was given to each 
pharmacist to complete the survey. Questionnaire was designed with various 
elements which can evaluate knowledge, attitude and practice of pharmacists 
towards ADR reporting. Results: A total of 256 community pharmacists were 
approached at selected community pharmacies per study criteria and were admin-
istered a questionnaire. Of 256, only 56 CPs (21.8%) responded to the survey. Of 56 
respondents, 37.5% were able to define ADR correctly, whereas 35.7% of pharmacists 
believed ADRs solely as allergic response. Only 46% of pharmacists could correctly 
identify potential risk factors responsible to cause ADRs and 57% of pharmacists 
were aware of the consequences of ADRs. Almost 93% of respondents admit that 
safety reporting is an important responsibility of pharmacist however, surprisingly 
almost 73.2% pharmacists were not aware of existing pharmacovigilance program 
in the country. As per 78.5% respondents ADR reporting in the community phar-
macies lead to additional workload. Looking at willingness to report, almost 50% 
of pharmacists expect incentives to get involve in the safety reporting and other 
50% feels it as professional responsibilities which do not require incentives. Among 
respondents only 20% of them had ever reported ADR to nearer national safety 
reporting centres. However, majority of CPs are interested to contribute for ADR 
reporting if appropriate training is provided. cOnclusiOns: Majority community 
pharmacists do not possess required knowledge on ADR reporting, its importance 
and national safety reporting program. There is a strong need to implement edu-
cational and regulatory interventions periodically to improve the understanding of 
safety reporting among CPs.
“baseline” year served as control data. Results: There were 1500 intervention and 
286 control participants with mean age (sd) 72.75 (7.82) and 73.39 years (7.31), and 
past year fall rates of 22.8% and 21.8%, respectively. Males comprised 23.1% of the 
intervention group and 24.8% of the control group. Majority were of Chinese eth-
nicity (86.7% of intervention and 81.1% of controls). Improvements from baseline 
to 52 weeks were significantly better (p< 0.05) for intervention participants than 
controls for the Six Minute Walk Test, Step Test, Falls Efficacy Score and Life Space 
Assessment; Safer Score was significantly better on follow-up for the intervention 
group. There was no significant difference in the Berg Balance, Timed-Up-And-Go, 
Chair Rise and EQ-5d. Intervention participants had significantly fewer falls in the 
third quarter of follow-up (95%CI of the difference= 0.00,0.10). Multivariate results 
revealed that the intervention group had significantly fewer falls for the entire 
follow-up year (Odds Ratio = 0.75, 95%CI = 0.58,0.97). cOnclusiOns: Results sug-
gest that the program improves physical performance and reduces the incidence of 
falls in the elderly. Residents may be empowered to take responsibility for prevent-
ing falls in their own community.
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Objectives: In 2012, the United States Food and Drug Administration (FDA) created 
a new expedited pathway of “Breakthrough Therapy Designation” (BTD) to enable 
an early approval of therapies which have shown substantial activity in early trials. 
The objective of this study was to assess the comparative effectiveness and pric-
ing of drugs with BTD. MethOds: The data for the number of granted BTDs was 
obtained from FDA.gov. The data for publically disclosed BTDs was obtained from 
sponsor’s press releases. For all products, the information for their mechanism 
of action, type of molecule, trial design, clinical efficacy and safety, and pricing 
and time to approval (for approved products) were obtained from peer-reviewed 
publications, conference abstracts, FDA and sponsor websites. Results: Since the 
establishment of the BTD pathway, 55 products have been granted breakthrough 
therapy designations (2012-2015), of which, 42 have been publically disclosed by the 
manufacturers and 6 have been approved by the FDA. In terms of indications, 43% 
are for cancer, 18% are for genetic diseases and 14% are for Hepatitis C Genotype 
1. The median time to approval for these three drug was ~5 years, significantly 
shorter than the 2012 median time to approval for priority review applications 
(6 years). The price premium was 30-50%, compared to other drugs in the same 
category. The six approved BTDs show 20-30% higher response rates than other 
products in the same category. The other products in the pipeline with established 
comparators show 36%-136% improvement in efficacy (based on active controls or 
previous trials). For approximately half of the products, comparative efficacy can-
not be determined because of no previous evidence for a product with efficacy in 
the targeted indications. cOnclusiOns: BTD is a promising pathway to shorten 
development time and provides early access, however, the high price could pose 
challenges for payers and patients.
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Objectives: To understand how comparative effectiveness research (CER) is being 
used by US managed care plans and pharmaceutical benefit managers (PBMs) to 
control the growth of healthcare costs and ensure appropriate utilization of products 
by pharmacy and therapeutics (P&T) committees. MethOds: Managed care (MC) 
medical and pharmacy directors (MDs+PDs) completed an online interactive survey. 
Topics included: advisor and plan information and current/future coverage of CER. 
The use of CER and evidence-based medicine (EBM) was evaulated using a 5-point 
likert scale (5= completely agreeing;1= completely disagreeing). Results: Fifty-four 
percent of respondents were MDs, the remainder mostly pharmacists. Most worked 
for a health plan (83.6%) and 39.6% of the plans were local; 35.4% national; and 25.0% 
regional. Public (Medicare and Medicaid) and private (Commercial) plans were rep-
resented. When asked to select the area emerging CER is expected to affect: value of 
care (29.8%), optimization/improvement of clinical guidelines (27.7%), appropriate-
ness of care (14.9%), pharmaceutical research and development (6.4%), medical and 
pharmacy benefit management (17.0%), and 4.3% uncertain. When asked about their 
agreement in “progress in obtaining usable information on CER of therapies” the 
results were slightly negative with 42.5% disagreeing (34%= somewhat,8.5%= com-
pletely), 38.3% agreeing (4.3%= completely,34%= somewhat), and 19.1% neutral. When 
asked if they expect their plan to use CER regularly in formulary decision making by 
2015, more than half (53.2%,14.9%= completely,38.3%= somewhat) agreed, 27.7% disa-
greed (23.4%= somewhat,4.3%= completely), and 19.1% were neutral. When asked 
to assess how “MC commonly using EBM today in coverage decision making” the 
results were more favorable with 79.2% agreeing (27.1%= completely,52.1%= some-
what); 14.6% neutral and 6.3% disagreeing (6.3%= somewhat,0%= completely). The 
most desired change to their plan’s/PBM’s P&T process was for increased use of CER; 
and a move toward contractual risk-sharing. cOnclusiOns: Formulary decision 
making in P&T committees is making progress in the use of comparative effective-
ness research. Results suggest that the acceptance of evidence-based medicine is 
valuable even if not comparative.
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Objectives: To investigate the perception of Romanian hospital managers towards 
under financing of the health sector and to identify the major drawbacks on differ-
ent aspects of hospital activity. The Romanian hospitals are paid using DRG system 
since 2009. This is the first attempt to obtain an empiric imagine of the oppinoin of 
the hospital’s managers regarding the effect of inadequate financing and its con-
sequences. MethOds: In the last trimester of 2014, we have sent a questionnaire 
with 25 questions to the top management of every Romanian hospital. The quiz 
was based on the results of a focus group held in September 2014 which included 
7 managers from different hospitals in Romania. Results: In 2013 in Romania 
there were 435 hospitals contracting services with the social insurance system. 
The questionnaires were sent by mail and we received 82 answers, which were sent 
back by mail or completed anonymously in a special online application. 85% (70 of 
82) of the managers indicated that the budget negotiated with the social insurance 
system is insufficient and causes some to major difficulties, some of them saying 
that is impossible to cover their expenses. As a result, 34,3% of the underfinanced 
hospitals had difficulties in acquiring the medication for their patients! 22,8% of 
those said that they faced difficulties in buying the drugs that cost more than 22 
Euro per day of treatment. 94% of the managers believed that the official tariffs do 
not cover the expenses required by the services. cOnclusiOns: Under financing 
of the Romanian hospitals is due to the inadequate tariffs established unilateral 
by the National Insurance House. As a result, many of the hospitals are generating 
debts. As the wages are paid with priority, the main effect of under financing is an 
inadequate amount of money spent on drugs.
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Objectives: Isolate, Identify and Determine the Antimicrobial Resistance Pattern of 
Salmonella Speciesfrom Selected Poultry Farms in Debre Zeit, Ethiopia. MethOds: 
Cross sectional study was conducted to isolate, identify and determine antimicrobial 
susceptibility testing of salmonella organisms from four selected poultry farms in 
Debre Zeit, Ethiopia. A total of 196 chickens were sampled from four purposively 
selected commercial poultry farms. Cloacal swab samples were collected from 
live chickens using sterile cotton tipped swabs moistened with buffered peptone 
water. The swabs were kept in properly plugged sterile test tubes. Then Isolation 
and Identification of Salmonella,Biochemical Confirmation, Polymerase Chain 
Reaction (PCR) and Antimicrobial susceptibility testing were conducted. Results: 
From a total of 196 cloacal swabs collected 50 (25.5%) were found to be positive for 
Salmonella organisms using culture method, and 15 (7.6%) Salmonella isolates were 
confirmed using biochemical tests. All culture and biochemical positive samples 
were further confirmed by Polymerase Chain Reaction (PCR) through amplifica-
tion of histidine transport operon as a target gene for the presence of salmonella 
isolates. From culture and biochemical positive samples, gel electrophoresis of the 
PCR product revealed the presence of 496bp segments in 13 (6.7%) Salmonella iso-
lates. The statistical analysis has revealed a significantly association between dif-
ferent age groups of chickens (X2 = 10.56; P = 0.005) and farms (X2 = 10.74; P= 0.013) 
with the percentage of Salmonella isolates. Most of the Salmonella isolates were 
found to be resistant against commonly used antimicrobials such as Sulfisoxazole, 
Chloramphenicol and Ampicillin followed by Tetracycline, Amoxicillin/Clavulanic 
acid and Cephalotin and more than half(69.3%) of the isolates were found to be 
multi-drug resistant. cOnclusiOns: The high prevalence of resistance to antimi-
crobial agents found in this study might be attributed to uncontrolled use of anti-
microbial agents as growth promoters in poultry farms. Therefore, proper treatment 
of chickens using appropriate antibiotics is then quite essential.
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Objectives: Regulators and Health Technology Assessment (HTA)/Payer stake-
holders are increasingly looking into Real Word Evidence (RWE) for RE and BR. 
Demonstrating quality, efficacy and safety plus cost effectiveness (‘4thhurdle’) is 
no longer sufficient to ensure market authorization and reimbursement. While 
some RWE stakeholders require randomized study approaches, e.g. to avoid allo-
cation bias, typically in the form of ‘pragmatic’ trials, others consider observa-
tional studies or accept indirect comparisons in the absence of head-to-head 
comparison results. However, it is unknown how frequently respective compara-
tive approaches are actually used. MethOds: To assess relative importance of 
observational, pragmatic and indirect methodologies for comparative RE and BR, 
we surveyed Medline using purpose related terms ‘relative/comparative effective-
ness’ or ‘benefit/risk’ in combination with methodology terms ‘observational/
non-interventional’, ‘pragmatic study/trial’, and ‘indirect comparison/network 
analysis’. Resulting publication numbers were analyzed, and selected abstracts 
were assessed qualitatively. Results: We focused on publication title analysis as 
all field searches yielded heterogenous results. Publication title hits were by far 
highest for OBS methodologies, followed by PRA and lowest for IND (13,247; 201; 
141), and higher for BR than for CE (3,017; 1,152). RE publications continuously 
increased over time with not more than 50 annual hits before 2005, but consist-
ently above 250 hits after 2013. Similarly, annual CE hits were below 20 before 2006, 
increased to 250 as of 2010, but tended to decrease after a peak in 2013. For RE, OBS 
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Objectives: The objective of this study was to analyze the implementation 
process and changes over a 4-year period of medication review services in an 
older adult population in German community pharmacies. Medication review 
is a patient-oriented service, designed to identify drug-related problems in a 
personal consultation. MethOds: This study focuses on adults older than 65 
years. Medication reviews were conducted in 254 pharmacies in Germany and 
analyzed over a 4-year period (2011 to 2014). Data extracted from medication 
reviews included patient demographics, drug-related problems (DRPs) detected 
by the pharmacy and pharmacy-related data. In addition to descriptive analysis, 
we performed binary multivariate logistic regression models to identify the main 
patient-, medication- and pharmacy-related predictors associated with the over-
all assessment of therapy. Results: A total of 2,931 medication reviews were 
analyzed with patients aged between 66 and 98 years. In the sample, the mean 
number of medicines taken by individuals was 6.08 with 66.6% of individuals tak-
ing five or more medicines. During the 4-year period, in 60.5% of all medication 
reviews (n = 2,931), DRPs were detected by participating pharmacies; significant 
differences could be determined between different years (p< 0.001) with scores 
ranging from 56.7% to 66.7%. In nearly half (47.1%) of the medication reviews, 
interactions were detected and the interaction potential was classified according 
to the ABDA database classification system. However, over-supply remains low 
at 6.9% of all medication reviews. Binary multivariate logistic regression analysis 
revealed different significant patient- and pharmacy-related predictors associ-
ated with overall assessment of therapy. cOnclusiOns: Findings indicate the 
potential to identify drug-related problems through medication review, based on 
a disclosure of all drugs taken by the patient. The extent of implementation of 
medication review in Germany cannot be regarded as satisfying at present. Hence, 
existing programs should be enhanced to increase the number of participating 
pharmacies and patients.
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Objectives: Grapefruit juice is known for its ability to interact with the phar-
macokinetics of many drugs. This work aims at characterising and synthesizing 
evidence on this interaction via systematic reviews and modelling. MethOds: 
Systematic review was performed to collect data on metabolic interactions 
between 35 drugs metabolized via the CYP3A4 metabolic pathway and grape-
fruit juice. Magnitude of interaction was defined as the ratio of areas under the 
curve with and without grapefruit juice. A Bayesian hierarchical meta-analysis 
model was used to quantify such interactions and the chemical-specific inter-
individual variability. Impact of real-world metabolic interactions on benefit 
risks on drugs was discussed. Results: Data from more than two hundred 
studies were collected, involving 35 widely used drugs. Grapefruit juice property 
to inhibit the CYP3A4 elimination translated into up to 20-fold higher internal 
doses hence raising potential safety concerns. Statistically significant magni-
tudes of pharmacokinetic effect ranged from 1.09 to 22.07. The mean magnitude 
of (CYP3A4-specific) interaction was estimated at 3.73 (95%-credibility interval 
[0.76-23.14]). cOnclusiOns: This work illustrates how real-life food-drug inter-
actions can severely impact real-world benefit/risk of drugs. Such information 
may be accounted for to inform risk management plans and to optimize early 
drug development.
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Objectives: Population aging has brought greater demand for admissions of 
patients with chronic diseases fleeing the routine therapeutic goals. The objec-
tive of this study is to evaluate the application of Karnofsky Performance Scale 
(KPS) to identify patients who need palliative care and avoiding therapeutic futil-
ity. MethOds: An observational vertical prevalence study made in June 2014 of 
clinical patients admitted in a public hospital in São Paulo city, by applying a brief 
and objective questionnaire directly to patient’s physicians in order to obtain a 
diagnosis of the clinical situation aspects, based on KPS. Results: According to the 
analyze of 259 questionnaires/patients (Female: 111 and male: 148) from all adult 
inpatient sectors in the hospital (medical wards, surgical wards and intensive care 
unit), we found: a) 62.55% with KPS ≥ 50 (without advanced disease); b) 2.70% with 
KPS = 40 (disease in progression to advanced); c) 1.16% with KPS = 30 (advanced 
disease, with no expectation of cure, unless performing organ transplants); d) 15.44% 
with KPS = 20 (advanced disease without an effective cure or treatment that can 
modifies the disease); e) 17.76% with KPS = 10 (death prediction in the present 
admission). Only one patient could not be classified. About 57% of patients were 
older than 50 years. cOnclusiOns: The KPS analysis showed 37.45% of the patients 
were with advanced disease condition and without possibility of cure who should 
be better treated in palliative care environments with more specific conditions 
for them, without using numerous and expensive drugs and procedures which 
only cause more suffering to these group of patients. To disseminate and applying 
the knowledge in palliative care will certainly contribute to a more rational use of 
therapeutic resources.
